Banned
i will run a dnp cycle soon
one capsule of 130 mg per day, during six weeks
with one hour cardio every day
like this, any side effects !
and IT INCREase the metabolism at 10 % more..
what do you think ????
in this case, do i need supplements with this smaller dose ?
Banned
nobody ????
HGH/IGF/Insulin Forum ~ AR-Hall of Famer
I'll move this thread to the right section for you.
And to answer your question, most people won't even cardio when on DNP, and doing DNP for 6 weeks is suicide. I would run DNP at about 250mg p/day for about 10 days. If you can't stand the sides, then lower the dose, if you feel ok then up the dose by a little. Do keep in mind that you may actually not feel any sides from DNP the first 3 - 4 days, if this is the case, do not increase the dose as DNP sides usually suddnley appear out of no where.
-Gear
Banned
130 mg is a waste.Please do your research with this drug,it`s clear you have not done any,as you can fry your organs inside your body and die.
Banned
Woops.I did not read 6 weeks.I`m not quite sure on this.As I have never done that type of thing.
Member
Couldn't a light dose be used with supplementing T3 for an extended time period and in this way maintaining a rise in metabolism without too much risk??
Just wondering
SHAGGY
Banned
i read the article of sv1, and he said that like this, it increase the metabolism and not risk
so i dont think that it s not safe
and it s not suicide,because my dose is safe,130 mg increase the temp body to 10 %...
please read this before to critiq my pct : http://forums.steroid.com/showthread...=dinitrophenol
Banned
goose, the girl with red hair is pretty...
Member
ive done a 7 week dnp cycle in the past..not something to recommend..after a few weeks even 200mg makes u incredible hot, the dnp is then quite well buildup into your system..
i definately gonna do from now on 2 weeks cycles...i really lost an incredible amount of strength during that long cycle..and the sweats didnt go away after stopping the dnp...1-2 months later the sweating dissapeared..
2 weeks cycle with 400-500mg dnp + igf is the way to go..btw slin or igf is almost needed while you on dnp, goose or another member explained it in detail why it's needed...
one thing i remember is that cataracts can develope when blood sugar is high..this happens when u are on dnp and igf/slin prefents this.. so the igf and slin combats the side effects..
Banned
Originally Posted by fred9
I read your great thread on your long term use with DNP,Very interesting.Agreed on the slin and IGF,infact as you know fred you cant really go hypo when on DNP with slin or IGF,so this is the perfect chance to run slin and IGF together with no risk.You have to take advatage of this,as you are diabetic with DNP.As you said Crystal DNP at 500 is just perfect,EASY....
Banned
United States Patent
4,673,691
Bachynsky June 16, 1987
Human weight loss inducing method
Abstract
A human weight reduction method in which 2,4-dinitrophenol and a thyroid hormone preparation are administered to the
patient. The dinitrophenol is administered in dosages sufficient to elevate the patient's body temperature, typically 250 mg
every other day. The thyroid hormone preparation preferably contains 3,5,3'-triiodothyronine and is administered in dosages
sufficient to substantially maintain the patient's serum T3 concentration originally present at treatment onset.
Inventors:
Bachynsky; Nicholas (1110 Pine Cir., Sea Brook, TX 77586)
Assignee: Bachynsky; Nicholas (Sea Brook, TX)
Appl. No.: 668501
Filed:
November 5, 1984
Current U.S. Class: 514/567; 514/909
Intern'l Class:
A61K 031/195
Field of Search:
514/728,909,567
References Cited
[Referenced By]
U.S. Patent Documents
4087554
May., 1978 Haydock et al. 514/728.
Other References
Chem. Abst. 66:82758c (1967)--Rossini et al.
Chem. Abst. 71:27671x (1969)--Tomita et al.
Chem. Abst. 77:109780v (1972)--Tiller et al.
Chem. Abst. 82:25791q (1975)--Wahl et al.
Chem. Abst. 88:167300b (1978)--Kaplan et al.
Chem. Abst. 89:191455x (1978)--Organesyan et al.
Chem. Abst. 100:168805y (1984)--Sydykov.
Chem. Abst. 102:56608w (1985)--Langer.
Simkins, S., "Dinitrophenol and Desiccated Thyroid in the Treatment of Obesity," JAMA 108, pp. 2110-2117
and 2193-2199 (1937).
Tainter, M. L. et al., "Dinitrophenol in the Treatment of Obesity," JAMA 105, pp. 332-336 (1935).
Tiller, F. W. et al., "The Effects of Noradrenaline and 2,4-Dinitrophenol on the Oxygen Consumption of
Different-Aged Rats After Treatment with Triiodothyronine or Methylthiouracil," Arch. Int. Pharmacodyn. 198,
pp. 377-384 (1972) (With Translation).
Wahl, R. et al., "Influence of Various Drugs on the Adsorption of Thyroid Hormones to Liver Mitochondria," Z.
Naturforsch, 29, pp. 608-617 (1974) (With Translation).
Schimmel, M. et al., "Thyroidal and Peripheral Production of Thyroid Hormones," Annals of Internal Medicine
87, pp. 760-768 (1977).
Arena, Jay M., Poisoning, pp. 86 and 92 (Charles C. Thomas, Springfield, Ill. (1978).
Cazeneuve, P. et al., "Sur les effets produits par l'ingestion et l'infusion intra-veineuse de trois colorants jaunes,
derives de la houille," C.R. Acad. Sci. 101, pp. 1167-1169 (1885).
Brobeck, J. R., "Food Intake as a Mechanism of Temperature Regulation," Yale Journal of Biology and
Medicine 20, pp. 545-552 (1948).
Cutting, W. C. et al., "Actions and Uses of Dinitrophenol," JAMA 101, pp. 193-195 (1933).
Diechmann, W. B. et al., Symptomatology and Therapy of Toxicological Emergencies, pp. 452-453 (Academic
Press, New York 1964).
Counsel on Pharmacy and Chemistry, "Dinitrophenol Not Acceptable for N.N.R.," JAMA 105, pp. 31-33 (1935).
Horner, W. D., "Cataract Following Dinitrophenol Treatment for Obesity," Archives of Opthalmology 16, pp.
447-461 (1936).
Negherbon, W. O., Handbook of Toxicology, vol. 3, pp. 303-308, (W. B. Saunders Co., Philadelphia 1959).
Perkins, R. G. "A Study of the Munitions Intoxications in France," Public Health Reports 34, pp. 2335-2374
(1919).
Sims, E. A. H. et al., "Endocrine and Metabolic Effects of Experimental Obesity in Man," Recent Progress in
Hormone Research 29, pp. 457-496 (1973).
Spector, W. S., Handbook of Toxicology, vol. 1, p. 118, (W. B. Saunders Co., Philadelphia, 1956).
Tainter, M. L. et al., "A Case of Fatal Dinitrophenol Poisoning," JAMA 102, pp. 1147-1149 (1934).
Physician's Desk Reference, 37th ed., pp. 1896-1897 (1983).
Primary Examiner:
Robinson; Douglas W.
Attorney, Agent or Firm:
Pravel, Gambrell, Hewitt & Kimball
Claims
I claim:
1. A method of inducing weight loss in a patient, comprising the steps of:
(a) administering 2,4-dinitrophenol or salt thereof at a rate ranging from about 60 to about 250 mg/day; and
(b) concurrently administering 3,5,3'-triiodothyronine to the patient at a rate ranging from about 25 to about 100 mcg/day.
2. The method of claim 1, wherein said 3,5,3'-triiodothyronine is substantially free of thyroxine.
3. The method of claim 1, wherein said 3,5,3'-triiodothyronine administration is at a rate ranging from about 50 to about 100
mcg/day.
4. The method of claim 1, wherein said dinitrophenol is administered at said rate with dosages given only on alternate days.
5. The method of claim 1, wherein said dinitrophenol is administered at said rate with primary dosages given on alternate days
and smaller, supplemental dosages given on the days immediately subequent to said alternate days.
6. The method of claim 1, wherein 2,4-dinitrophenol is administered.
7. A method of inducing weight loss in a patient, comprising the steps of:
(a) administering 2,4-dinitrophenol to the patient at a rate ranging from about 125 to about 250 mg/day; and
(b) concurrently administering 3,5,3'-triiodothyronine substantially free of thyroxine to the patient at a rate ranging from about
50 to about 100 mcg/day.
8. The method of claim 7, wherein said dinitrophenol and said 3,5,3'-triiodothyronine are administered at initial rates of about
250 mg of said dinitrophenol every other day and about 50 mcg 3,5,3'-triiodothyronine per day, and following 2-12 weeks of
said administration at said initial rates, are administered at subsequent rates of about 250 mg of said dinitrophenol every other
day alternated with about 125 mg of said dinitrophenol on subsequent days and about 100 mcg 3,5,3'-triiodothyronine per day.
Description
This invention relates to a method of inducing weight loss in patients by the concurrent administration of 2,4-dinitrophenol and
3,5,3'-triiodothyronine.
BACKGROUND OF THE INVENTION
Obesity is a common problem. Simply stated, obesity is an excess accumulation of adipose tissue which contains fat stored in
the form of triglycerides. The number of cells in the body is determined at least by late adolescence and while the number of
adipocyte cells may increase, it does not decrease. Thus, weight gain can result from an enlargement of adipocyte cells or an
increase in their number. Typically, obese individuals have hypertrophic cells and the severely obese have an increase in
adipose cell number as well as hypertrophy. An obese patient only reduces the fat in his cells when he loses weight. Further, he
may not ever lose the tendency to gain weight.
Body weight is regulated by an endogenous body mechanism. Physiological and neurological properties establish and maintain
a given weight. Briefly stated, glycerol which is released during hydrolysis of triglycerides and adipose tissue is widely
believed to regulate caloric intake and metabolism. Others have postulated that caloric intake is affected by both body
temperature and environmental temperature. In addition, cell size and number affect energy regulation. Weight gain cannot be
predicted solely on the amount of calories ingested.
In normal persons, thermogenesis is an adaptive mechanism which increases the metabolic rate after overeating. While a
normal person will experience an increase in thermogenesis following increased caloric intake, the obese either has a
substantially decreased thermogenic mechanism or lacks this particular mechanism entirely.
The use of dinitrophenol to treat obesity is known. Dinitrophenol is known to elevate the body temperature and produces a
marked increase in caloric metabolism. However, ingestion of massive amounts of dinitrophenol causes toxicity by the
uncoupling of oxidative phosphorylation in the mitochondria of cells. Because of this toxicity, excessive amounts can result in
profuse diaphoresis, fever, thirst, tachycardia and respiratory distress which can lead to hyperpyrexia, profound weight loss,
respiratory failure and death. The minimum fatal human oral dose is estimated at one to three grams (approximately 20-30
mg/kg).
In methods heretofore known to using dinitrophenol to induce weight loss, while initial daily dosages have usually been much
less than the toxic amount, about 100-250 mg, as the treatment progressed the patient normally developed a tolerance for
dinitrophenol and the dosage was increased to obtain the same results. This increased dosage led to an increased frequency of
toxic symptoms and general disuse of dinitrophenol in inducing weight loss.
It has also been known to use drugs with thyroid hormone activity for the treatment of obesity. However, as described in
Physicians' Desk Reference, Medical Economics Co. Inc., (Oradell, N.J.), 37th Ed. (1983), in euthyroid patients, it is well
established that doses within the daily hormonal requirements are ineffective for weight reduction. However, larger doses may
produce serious or even life-threatening manifestations of toxicity.
SUMMARY OF THE INVENTION
The present invention avoids the necessity of increased dosages of dinitrophenol and the concomitant toxicity problems
associated therewith as treatment progresses while obtaining improved results. It has been discovered that the use of
dinitrophenol induces hypothyroidism which can be prevented by concurrently administering thyroid hormone preparation
with the dinitrophenol.
Briefly, the present invention is a method of inducing weight loss in patients, including the steps of administering
dinitrophenol to the patient in an amount sufficient to clinically increase thermogenesis of the patient, and concurrently
administering a thyroid hormone preparation to the patient in an amount sufficient to substantially maintain the serum
concentration of 3,5,3'-triiodothyronine of the patient originally present at treatment onset.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
It has been discovered that the ingestion of dinitrophenol induces hypothyroidism. Athough it is not fully understood, it is
believed that the normal thyroid gland produces both thyroxine (referred to herein as T4) and 3,5,3'-triiodothyronine (referred
to herein as T3). However, approximately eighty percent of the serum T3 present in the body is produced by the extrathyroidal
monodeiodination of T4 to T3. When dosages of dinitrophenol are taken, hypothyroidism is induced, not by a reduction in
activity of the thyroid, but by a reduction of the rate of extrathyroidal conversion of T4 to T3. While both T4 and T3 are
biologically active, T3 is much more active than T4. Thus, the reduction in serum T3 concentration induced by taking
dinitrophenol substantially offsets the metabolic effect of the dinitrophenol. By analogy, the reduction in serum T3
concentration is similar to that observed in fasting patients. Typically, normal serum T3 concentration ranges from about 70 to
about 200 ng/dl.
It has further been discovered that deficient serum T3 concentrations resulting from administration of dinitrophenol can be
restored to normal concentrations by concurrently administering a thyroid hormone preparation therewith.
In practicing the method of this invention, dinitrophenol is administered to the patient. The metabolically active dinitrophenols
suitable for use in the invention include 2,4-dinitrophenol and the salts thereof. By the term administration is meant any
suitable manner of introducing the medication into the patient's body, including orally (p.o.) and topically. The preferred
manner of administering dinitrophenol is orally, as in the form of a tablet or capsule.
The amount of dinitrophenol given should be sufficient so that the patient experiences increased body temperature. Preferably,
the body temperature is elevated approximately 1.degree. F. The dose of dinitrophenol required to obtain this result varies from
patient to patient, depending on factors such as, for example, weight, age, health, environmental conditions, physical activity,
nutrition, and psychological state, but will normally be in the range of from about 60 to about 500 mg per day, or about 0.60 to
about 5.0 mg/kg of body weight per day. Preferably, the dinitrophenol is administered in daily or alternating daily dosages,
insuring that no cumulative effective results, such as excessive thermogenesis.
It is essential that the amount of dinitrophenol administered not exceed toxic doses. In a few patients, adverse reactions may
occur at dosages of dinitrophenol which are not effective to elevate the body temperature, contraindications including any
clinical state in which there is hypermetabolism, such as hyperthyroidism, ongoing infections, and pregnancy, and any other
clinical conditions such as heart disease, chronic obstructive pulmonary disease, Addison's disease, liver disorders, or renal
failure. Most are safely treated with suitable results from the aforementioned dosages.
Concurrently with the administering of the dinitrophenol, or shortly thereafter, a thyroid hormone preparation is administered
to the patient. As used herein, the term thyroid hormone preparation includes any suitable preparation which restores the serum
T3 concentration, including preparations containing 3,5,3'-triiodothyronine, thyroxine, derivatives thereof or combinations
thereof. Preferably, the thyroid hormone preparation contains T3. Because of the varying potency of such preparations,
dosages of thyroid harmone preparation are reported herein on a T3 equivalent basis.
The thyroid hormone preparation is administered in an amount sufficient to maintain the pretreatment serum T3 concentration
in the patient, typically about 70-200 ng/dl in normal patients. Generally, from about 25 to about 200 mcg T3 equivalent per
day, or from about 0.3 to about 2.7 mcg T3 equivalent per kilogram of body weight per day, is sufficient. Preferably, the
thyroid hormone preparation is administered daily. In an especially preferred embodiment, the thyroid hormone preparation is
administered orally with the dinitrophenol.
As described above, the rate of extrathyroidal conversion of T4 to T3 may vary as treatment with the dinitrophenol progresses.
Thus, it may be necessary to increse or decrease the dosage of the thyroid hormone preparation accordingly.
It is preferred that in the practice of the method of this invention, the patient be closely monitored, especially in the initial
stages of treatment. Recommended pretreatment and initial treatment protocol includes physical examination,
electrocardiogram, and stress electrocardiogram if indicated, complete blood count, urinalysis, thyroid function studies (T3, T4
and reverse T3), serum electrolytes, HDL cholesterol, serum creatinine, blood urea nitrogen, uric acid, calcium, pulmonary
function tests and liver function tests including liver enzymes, biliribin, and alkaline phosphatase.
In an especially preferred embodiment, the patient is started on initially lower dosage rates of dinitrophenol, about 250 mg
every other day, and thyroid hormone preparation, about 25-50 mcg/day on a T3 equivalent basis. After 2-12 weeks of this
treatment, if no adverse reactions are noted, the dosage rates may be increased to about 250 mg dinitrophenol alternated daily
with about 125 mg, i.e. 250 mg on even-numbered days and 125 mg on odd-numbered days, and to about 100 mcg/day thyroid
hormone preparation on a T3 equivalent basis. When the weight goal of the patient is achieved, the administration of the
dinitrophenol may be discontinued, and the thyroid hormone preparation continued to maintain the patient's weight. While
dietary control need not be strict, weight loss and weight maintenance are facilitated by moderate caloric intake of less than
about 1800 calories per day, during and following treatment.
This method is illustrated by way of the case histories which follow.
Case 1
A white female 31 years of age with a weight in excess of 200 pounds had attempted to loss weight with various diet plans.
She had only been able to achieve about a 20-pound loss, and had immediately regained the weight. The patient was
nulliparous and had no ongoing medical problems. Upon physical examination, she had a weight of 208.5 pounds, a height of 5
feet, 3 inches, and a blood pressure of 132/80, without any goiter. Laboratory analyses, including complete blood count, liver
profile, serum electrolytes, kidney function tests and thyroid function tests, were all within normal limits. Because of her
familial history of heart disease, she underwent a stress electrocardiogram which was normal other than early fatigue and calf
cramping.
The patient was started on CYTOMEL brand of liothyronine sodium (manufactured by Smith, Kline and French), 50 mcg/day
p.o., and on 2,4-dinitrophenol, 250 mg every other day p.o. On the 19th day of medication, the patient had normal vital signs
and the dosages were increased to 100 mcg/day liothyronine, and 250 mg/day dinitrophenol alternated every other day with
125 mg/day. The patient was subsequently maintained on these dosages and returned for follow-up examinations
approximately every 3 weeks. The weight loss history is seen in Table 1. After 241 days of medication, the patient has
achieved her weight goal of 135 pounds. Administration of the dinitrophenol was discontinued and the patient was maintained
on liothyronine, 100 mcg/day p.o. No weight gain was subsequently observed.
TABLE 1
______________________________________
Day Weight (lbs)
______________________________________
1 208 1/2
19 202 1/2
35 196 1/2
49 189 1/2
69 184
92 175
113 167
134 160
155 152 1/2
180 148
206 146
241 135
______________________________________
Case 2
A male 40 years of age with a weight of approximately 250 pounds had attempted to lose weight with a variety of diet plans
and diet medications. Success had been limited to 5-10 pound weight losses, with immediate regain. On physical examination,
the patient has a height of 5 feet, 10 inches, a weight of 255 pounds and a blood pressure of 160/100. Complete blood count,
SMAC, serum electrolytes, thyroid function tests, glucose tolerance tests and stress electrocardiogram were normal.
The patient was started on liothyronine, 50 mcg/day p.o., and on dinitrophenol, 250 mg every other day p.o. After two weeks,
the blood pressure returned to normal (130/80), and the dosages were increased to 100 mcg/day liothyronine and 250 mg
dinitrophenol alternated daily with 125 mg. The weight loss history is presented in Table 2. Once the weight goal of 167
pounds had been achieved, the patient was taken off the dinitrophenol administration and the 100 mcg/day liothyronine
medication was maintained. The patient was instructed to restrict caloric intake to approximately 1800 calories per day. No
subsequent weight gain was observed.
TABLE 2
______________________________________
Day Weight (lbs)
______________________________________
1 255
14 241
30 232
44 227
65 220
76 214
97 208
125 203
153 197 3/4
181 193
209 189
279 178
321 167
______________________________________
Case 3
A white male 38 years of age with a weight of approximately 342 pounds had made numerous attempts to lose weight "with all
methods" without any success. Upon physical examination, the patient had a weight of 352 pounds, a height of 5 feet, 11
inches and a blood pressure of 150/110. Other than a slight enlargement of the heart on X-ray and +3 pitting edema, the
physical examination was unremarkable. Laboratory analysis initially revealed a blood sugar of 372 with a glycohemoglobin
of 14.3 (normal 4.4-8.2). The remaining tests, including stress electrocardiogram, were within normal limits. The patient was
started on liothyronine, 50 mcg/day p.o., and dinitrophenol, 250 mg every other day, and was instructed to restrict his caloric
intake to approximately 1800 calories per day. On the 59th day of treatment, the dosages were increased to 100 mcg/day
liothyronine, and 250 mg/day dinitrophenol alternated every day with 125 mg. The patient's weight loss history is presented in
Table 3. Following treatment, the dinitrophenol administration was discontinued and the patient was maintained on
liothyronine, 100 mcg/day p.o. and instructed to maintain his caloric intake to approximately 1800 calories per day. No
subsequent weight gain was observed.
TABLE 3
______________________________________
Day Weight (lbs)
______________________________________
1 354
24 333
38 314
59 317
80 297 1/4
101 288
122 275
143 260 1/2
164 254
185 243 1/2
206 246
227 235 1/2
248 234
269 229
290 222
______________________________________
The above cases illustrate the effectiveness of the method with obese patients unable to reduced their weight by conventional
methods.
Having described any weight loss method above, many variations in the details thereof will occur to those skilled in the art. It
is intended that all such variations which fall within the scope and spirit of the appended claims be embraced thereby.
* * * * *
I think this is could help you.Remember this study is for very VERY fat people.
Banned
yes i read it, but read this
4. This is for all you office guys....I know exactly how you feel.
200mg/day will make most people sweat in a suit if they
move around a lot, however 100mg/day WILL NOT.
I have personally tried this dosage and I didn't even FEEL
IT.
At 100mg/day, dehydration isn't really an issue.
Steroids CAN ACTUALLY be taken at this dosage,
and muscle gain is POSSIBLE.
Your metabolism is amped up by 10%
Compared to 3% to ECA, 4% to Clen, and 7-8% from
Beta-agonists+T3
And to boot, DNP DOES NOT give you ANY of the side
effects associated with high-doses of stimulants
because IT DOES NOT WORK THROUGH the
cardiovascular system.
i think that s clear, dnp AT low dose can help you to increase metabolism
Last edited by the.tunisian.muscle; 02-18-2007 at 07:07 AM.
Member
Yes, even at a low dose the DNP will influence your metabolism, what I have been thinking about is that maybe when doing a low dose of DNP for an extended timeframe you should supplement with a low dose of T3, the reason being that after a while the DNP would inhibit your endogenous(sp??) T4 being converted to T3, but I don't know how pronounced this effect would be at a low dose.
If this effect would be very strong at a low dose wouldn't it mean that by taking the DNP at a low dose and not supplementing with T3 the rise in metabolism would be small because even if the DNP rises metabolism(keep in mind it is dosed low), a substantial amount of your metabolism would be lowered again by the dropping of ones own T3 levels??
Don't know though, just wondering.
Have you started your DNP cycle yet tunisian??
SHAGGY
edit; spelling
Last edited by SHAGGY; 02-18-2007 at 12:30 PM.
Banned
not yet,i wait my dnp, it comes in 4 days !
shaggy, speak with me french forasmuch as you are from belgium.
thanks.
Banned
ANd how much fat did you lose it ????
WHAT mean "to go btw" ????
Member
btw=by the way..
don;t know exactly how much fat i lost i think i started @ 10-12%bf..at the end of the ride i was on approx5%..
nice posts goose!!
Member
I will try tunisian, but my french is pretty bad, and if we speak french it is offcourse better limited to PM's, otherwise most board members would not understand what we are saying. Do you speak any dutch??
Keep us updated on the DNP, is it crystal or powder version??
SHAGGY
Banned
spreek je nederlands ????
dnp, i dunno if it s crystal or powder but i guess that s powder because caps are yellow
(i know the color because my friend has order from him)
so if fred lost a lot of fat with his cycle, it means that my idea (dnp 130 mg on 6 weeks) is not bad Because my cycle look like his cycle
but now, i think that i will couple it with t3, and igf and slin
i guess that it s the good combo
no ?????
Last edited by the.tunisian.muscle; 02-18-2007 at 10:08 AM.
Member
"Spreek je nederlands??"
Translation; "Do you speak dutch?"
Ja geen probleem, als je verder wil spreken stuur me dan een PM, zo storen we de rest niet met ons nederlands.
Translation; " Yes, no problem, if you wish to speak in dutch more, send me a PM, this way we won't bother the others with our Dutch."
SHAGGY
Anabolic Member
i use dnP but i just wanted you to be aware of Bachynsky and his thoughts on dnp uses in obesity treatment and cancer treatment.
check out this http://www.quackwatch.org/01Quackery...ncer/icht.html
http://www.casewatch.org/doj/shantha/indictment.shtml
Member
That is supposedly a good combo, but if you don't have any experience with all of those before and on their own, I really wouldn't combine them. Use the DNP on its own for two weeks at a light dose to see how you react to it and to get familiar with how it makes you feel, then take a break for a few weeks, if you still want to lose weight you can try it again and if you really want, incorporate one of the other aids in at a time. Seems to be a much safer way of doing it than to jump on everything the first time you use DNP, it is a harsh substance on its own, in combination it is more difficult to handle it would seem to me.
SHAGGY
Banned
ok i will do it
but nederlands is netherlands and not deutsch...no ?
Member
In English;
Dutch= Nederlands(the language spoken in Belgium and The Netherlands/Holland)
German= Duits(the language spoken in Germany).
By the way; you have PM, feel free to ask me any questions in Dutch(Nederlands) via PM.
SHAGGY
Banned
dank u (thanks)
Member
Geen probleem, graag gedaan. (No problem, it was my pleasure.)
SHAGGY
There are currently 1 users browsing this thread. (0 members and 1 guests)
Posting Permissions
Reply With Quote